Introduction {#H1-1-ZLD200092}
============

With routine screening mammography, nearly 1 in 5 breast cancer cases are invasive tumors smaller than 1 cm.^[@zld200092r1]^ However, for hormone receptor (HR)--positive, *ERBB2*(previously *HER2* or *HER2/neu*)--negative, node-negative breast cancer, pT1a tumors (ie, tumors measuring more than 0.1 cm but not more than 0.5 cm in greatest dimension) were underrepresented in prior prospective trials, ranging from 6% to 13% of participants in prior trials.^[@zld200092r2],[@zld200092r3]^ In the absence of strong prospective evidence, the National Comprehensive Cancer Network recommends consideration of adjuvant endocrine therapy for patients with pT1aN0 breast cancer without the routine use of multigene assay.^[@zld200092r4]^ Thus, we sought to examine the association of overall survival (OS) with endocrine therapy in this cohort of patients.

Methods {#H1-2-ZLD200092}
=======

In this cohort study, we queried the National Cancer Database query for women diagnosed with HR-positive, *ERBB2*-negative pT1aN0 breast cancer between January 2010 and December 2015 who were treated with or without adjuvant endocrine therapy. Follow-up occurred until December 2016; analysis was performed from January 2020 to March 2020. Institutional review board approval was obtained from the Roswell Park Comprehensive Cancer Center; informed consent was not needed because data in the National Cancer Database are deidentified and freely available to approved Commission on Cancer--affiliated investigators. Our study follows the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline. The primary end point was overall OS. Kaplan-Meier method, Cox multivariable analysis, and interaction analysis were performed for survival outcomes. To address potential confounders, the logit of propensity score matched all variables in a 1:1 ratio without any replacement. The standardized mean difference of variables was less than 0.1. To address immortal time bias, reanalysis was performed after excluding those who survived less than 6 months as a conditional landmark. Sensitivity analysis was also performed on a subgroup of patients who refused endocrine therapy. All analyses were performed with R version 3.6.1 (R Project for Statistical Computing). Statistical significance was set at 2-sided *P* \< .05 (eAppendix in the [Supplement](#note-ZLD200092-1-s){ref-type="supplementary-material"}).

Results {#H1-3-ZLD200092}
=======

A total of 42 708 patients, comprising 36 985 (86.6%) White patients and with a median (interquartile range \[IQR\]) age of 63 (54-71) years, met our criteria, including 31 509 patients (73.8%) and 11 199 patients (26.2%) with and without endocrine therapy, respectively. The median (IQR) follow up was 42.1 (24.2-62.1) months. On Cox multivariable analysis (adjusted for facility type, facility volume, age, race, income, insurance, Charlson-Deyo comorbidity score, year of diagnosis, surgery, radiation, number of lymph nodes examined, and hospital readmission), the receipt of adjuvant endocrine therapy was associated with improved OS (hazard ratio \[HR\], 0.69; 95% CI, 0.63-0.76; *P* \< .001). The [Table](#zld200092t1){ref-type="table"} describes 7544 matched pairs, in whom similarly improved OS was observed (HR, 0.76; 95% CI, 0.66-0.88; *P* \< .001) ([Figure](#zld200092f1){ref-type="fig"}). There was no statistically significant interaction of endocrine therapy with other baseline characteristics, such as age, comorbidity score, or tumor grade. After excluding 1659 patients (3.9%) with survival of less than 6 months, the addition of adjuvant endocrine therapy remained associated with improved OS (HR, 0.74; 95% CI, 0.67-0.81; *P* \< .001). Of 11 199 patients treated without endocrine therapy, 3492 patients (31.2%) recommended therapy by a clinician refused the treatment. Compared with those who received endocrine therapy, similar findings were observed among those refusing the treatment favoring endocrine therapy (HR, 0.80; 95% CI, 0.69-0.94; *P* = .007).

###### Baseline Characteristics for Matched Cohorts

  Characteristic                                                   Patients, No. (%)   Standardized mean difference   
  ---------------------------------------------------------------- ------------------- ------------------------------ --------
  Facility volume                                                                                                     
  Low                                                              358 (4.7)           359 (4.8)                      .001
  Intermediate                                                     1542 (20.4)         1544 (20.5)                    
  High                                                             5644 (74.8)         5641 (74.8)                    
  Facility type                                                                                                       
  Nonacademic                                                      5325 (70.6)         5325 (70.6)                    \<.001
  Academic                                                         2123 (28.1)         2123 (28.1)                    
  Not available                                                    96 (1.3)            96 (1.3)                       
  Age, y                                                                                                              
  \<50                                                             974 (12.9)          973 (12.9)                     \<.001
  50-74                                                            5057 (67.0)         5057 (67.0)                    
  ≥75                                                              1513 (20.1)         1514 (20.1)                    
  Charlson-Deyo comorbidity score                                                                                     
  0                                                                6673 (88.5)         6671 (88.4)                    .001
  1                                                                758 (10.0)          759 (10.1)                     
  ≥2                                                               113 (1.5)           114 (1.5)                      
  Income, median (IQR)[^a^](#zld200092t1n1){ref-type="table-fn"}                                                      
  ≥\$50 353                                                        5528 (73.3)         5525 (73.2)                    \<.001
  \<\$50 353                                                       2014 (26.7)         2017 (26.7)                    
  Not available                                                    2 (0.0)             2 (0.0)                        
  Insurance                                                                                                           
  None                                                             18 (0.2)            18 (0.2)                       .003
  Private                                                          3638 (48.2)         3634 (48.2)                    
  Public                                                           3871 (51.3)         3874 (51.4)                    
  Not available                                                    17 (0.2)            18 (0.2)                       
  Histology                                                                                                           
  Ductal or lobular                                                7165 (95.0)         7165 (95.0)                    \<.001
  Others                                                           379 (5.0)           379 (5.0)                      
  Grade                                                                                                               
  Well differentiated                                              4150 (55.0)         4150 (55.0)                    .002
  Moderately differentiated                                        2838 (37.6)         2842 (37.7)                    
  Poorly differentiated                                            244 (3.2)           243 (3.2)                      
  Not available                                                    312 (4.1)           309 (4.1)                      
  Race                                                                                                                
  White                                                            7068 (93.7)         7065 (93.7)                    \<.001
  Black                                                            288 (3.8)           288 (3.8)                      
  Others                                                           178 (2.4)           181 (2.4)                      
  Not available                                                    10 (0.1)            10 (0.1)                       
  Year                                                                                                                
  2010-2012                                                        3538 (46.9)         3531 (46.8)                    .002
  2013-2015                                                        4006 (53.1)         4013 (53.2)                    
  Lymph nodes examined                                                                                                
  ≤2                                                               4542 (60.2)         4542 (60.2)                    .004
  \>2                                                              2992 (39.7)         2991 (39.6)                    
  Not available                                                    10 (0.1)            11 (0.1)                       
  Hormone receptor                                                                                                    
  ER+/PR+                                                          6979 (92.5)         6977 (92.5)                    .001
  ER+ or PR+ only                                                  565 (7.5)           567 (7.5)                      
  Surgery                                                                                                             
  Lumpectomy                                                       4610 (61.1)         4609 (61.1)                    .001
  Mastectomy                                                       2934 (38.9)         2933 (38.9)                    
  Others                                                           0                   2 (0.0)                        
  Margin                                                                                                              
  Negative                                                         7498 (99.4)         7497 (99.4)                    .02
  Positive                                                         45 (0.6)            44 (0.6)                       
  Not available                                                    1 (0.0)             3 (0.0)                        
  Radiation                                                                                                           
  None                                                             4082 (54.1)         4083 (54.1)                    .001
  External beam                                                    3024 (40.1)         3025 (40.1)                    
  Others                                                           438 (5.8)           436 (5.8)                      
  Radiation dose, median (IQR) Gy                                  60.0 (48.1-62.6)    60.0 (50.4-62.0)               .008
  Readmission within 30 d                                                                                             
  None                                                             7466 (99.0)         7465 (99.0)                    .003
  Unplanned                                                        21 (0.3)            21 (0.3)                       
  Planned                                                          43 (0.6)            43 (0.6)                       
  Others                                                           2 (0.0)             2 (0.0)                        
  Not available                                                    12 (0.2)            13 (0.2)                       
  Postoperative inpatient duration, d                                                                                 
  \<1                                                              4341 (57.5)         4445 (58.9)                    .01
  ≥1                                                               2498 (33.1)         2414 (32.0)                    
  Not available                                                    705 (9.3)           685 (9.1)                      

Abbreviations: ER, estrogen receptor; IQR, interquartile range; PR, progesterone receptor.

Median income based on data from the 2016 American Community Survey.
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Discussion {#H1-4-ZLD200092}
==========

To our knowledge, this is the largest cohort study to evaluate the OS outcome of endocrine therapy for pT1aN0 breast cancer using a national registry database. The survival benefit identified in our study supports the National Comprehensive Cancer Network's recommendation of adjuvant endocrine therapy in this cohort^[@zld200092r4]^ and is consistent with favorable outcomes previously described.^[@zld200092r5]^ However, the benefit of adjuvant endocrine therapy should be weighed against potential long-term toxic effects in select patients.^[@zld200092r6]^ Limitations of our study include unavailable variables such as performance status, toxicity profiles, and tumor recurrences, which may lead to unmeasured confounding despite matching. Reanalysis using a cohort of patients who declined recommended endocrine therapy revealed consistent findings. The risk of relapse from very small tumors remains significant enough to warrant adjuvant therapy. Our study further affirms clinicians' decisions to recommend adjuvant endocrine therapy in this cohort of patients.
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Click here for additional data file.
